[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 55 of about 55
1. Doddi S, Singhal T, De Silva C, Smedley F, Sinha P, Leslie M: Small cell carcinoma of the anus: a case report. Cases J; 2009;2:9396

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma of the anus: a case report.
  • Small cell carcinoma of the anus is a very rare but aggressive tumour.
  • We present a case of a 60-year old lady with small cell carcinoma of the anus.
  • She had no metastatic disease on presentation.
  • Chemotherapy remains the mainstay of treatment for small cell carcinoma of the anus with or without metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1068-76 [17614337.001]
  • [Cites] Histopathology. 2007 Jan;50(1):163-74 [17204029.001]
  • [Cites] World J Gastroenterol. 2005 May 28;11(20):3156-8 [15918209.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Dec;5(12):692-3 [18852720.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Surg Today. 2002;32(1):72-4 [11871823.001]
  • [Cites] Surg Today. 1993;23(1):85-8 [8384908.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):635-42 [8026228.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2730-9 [15226341.001]
  • (PMID = 20076782.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806881
  •  go-up   go-down


2. Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S: Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer; 2010 Dec 07;103(12):1858-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review.
  • BACKGROUND: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC).
  • However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years.
  • This systematic review examines current prognostic markers in SCC of the anus.
  • METHODS: an extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.
  • CONCLUSIONS: an array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer.
  • [MeSH-major] Anus Neoplasms / mortality. Biomarkers, Tumor. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Cancer Resaerch UK.
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4268-75 [18626007.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):33-40 [19116625.001]
  • [Cites] Angiogenesis. 2008;11(4):321-35 [18925424.001]
  • [Cites] Mol Carcinog. 2009 Jan;48(1):45-55 [18506774.001]
  • [Cites] Pathol Oncol Res. 2008 Dec;14(4):345-54 [18493868.001]
  • [Cites] Rom J Morphol Embryol. 2009;50(1):31-9 [19221643.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2009 May;37(5):544-56 [19233691.001]
  • [Cites] Biochim Biophys Acta. 2009 Apr;1792(4):229-39 [19419697.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3725-32 [19458054.001]
  • [Cites] Curr Drug Targets. 2009 Jul;10(7):581-9 [19601762.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Dec;65(1):197-9 [19727729.001]
  • [Cites] Lancet Oncol. 2009 Oct;10(10):1001-10 [19796752.001]
  • [Cites] Adv Genet. 2009;67:1-27 [19914448.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6213-21 [19884544.001]
  • [Cites] Br J Cancer. 2010 Jan 19;102(2):361-8 [20010949.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Cancer Biol Ther. 2010 Jan;9(1):23-30 [19923884.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):618-35 [15234243.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1239-44 [15292923.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer. 1977 Oct;40(4):1621-8 [332328.001]
  • [Cites] Int J Cancer. 1983 Jan 15;31(1):13-20 [6339421.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):782-5 [3367186.001]
  • [Cites] Cell. 1989 Jun 30;57(7):1083-93 [2525423.001]
  • [Cites] Clin Cancer Res. 2010 Mar 15;16(6):1745-55 [20215558.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Dig Dis Sci. 2010 Apr;55(4):1098-105 [19399614.001]
  • [Cites] Head Neck Oncol. 2010;2:8 [20398256.001]
  • [Cites] N Engl J Med. 2010 Jul 1;363(1):24-35 [20530316.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Clin Chem. 2000 Mar;46(3):313-8 [10702516.001]
  • [Cites] J Surg Oncol. 2000 Jun;74(2):163-6 [10914829.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Health Syst Pharm. 2000 Nov 15;57(22):2063-76; quiz 2077-9 [11098307.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1768-72 [11100055.001]
  • [Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Dec;19(4):471-5 [11277325.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2272-81 [11304781.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):506-12 [11330577.001]
  • [Cites] Histopathology. 2001 Jul;39(1):43-9 [11454043.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1355-8 [11677963.001]
  • [Cites] Nat Rev Neurosci. 2002 Jan;3(1):24-33 [11823802.001]
  • [Cites] Cancer Lett. 2002 May 8;179(1):1-14 [11880176.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] J Oral Pathol Med. 2003 Sep;32(8):468-74 [12901728.001]
  • [Cites] Med Oncol. 2003;20(3):221-31 [14514971.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6489-96 [14695153.001]
  • [Cites] Dis Colon Rectum. 1991 Feb;34(2):126-31 [1993409.001]
  • [Cites] Oncogene. 1991 Jul;6(7):1251-7 [1650445.001]
  • [Cites] EMBO J. 1992 Mar;11(3):961-71 [1312467.001]
  • [Cites] Acta Oncol. 1992;31(3):333-5 [1622654.001]
  • [Cites] Int J Colorectal Dis. 1993 Jul;8(2):98-102 [7691975.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):697-709 [7881344.001]
  • [Cites] Cancer Metastasis Rev. 1995 Mar;14(1):3-15 [7606818.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1096-100 [7576999.001]
  • [Cites] Virchows Arch. 1996 May;428(2):85-9 [8925129.001]
  • [Cites] Oncology. 1996 Sep-Oct;53(5):369-73 [8784470.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Int Surg. 1997 Jul-Sep;82(3):275-9 [9372374.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1998 Apr;77(8):1333-6 [9579842.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1831-5 [9815570.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] J Exp Clin Cancer Res. 1999 Mar;18(1):47-52 [10374676.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):309-14 [10487550.001]
  • [Cites] J Pathol. 2005 Jan;205(2):123-9 [15643673.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):20-3 [15923158.001]
  • [Cites] Acta Histochem. 2005;107(2):87-93 [15950051.001]
  • [Cites] Cancer Invest. 2005;23(4):338-51 [16100946.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]
  • [Cites] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):942-9 [16648870.001]
  • [Cites] Oncol Rep. 2006 Sep;16(3):443-9 [16865241.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5034-42 [17075123.001]
  • [Cites] BMC Med Res Methodol. 2007;7:10 [17302989.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1114-20 [17296974.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):376-86 [18223558.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1264-73 [18349847.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):946-53 [18396036.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • (PMID = 21063399.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  • [Other-IDs] NLM/ PMC3008609
  •  go-up   go-down


3. Abbas A, Yang G, Fakih M: Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis. Oncology (Williston Park); 2010 Apr 15;24(4):364-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal cancer in 2010. Part 1: Overview, screening, and diagnosis.
  • Although anal cancer is a rare disease, its incidence is increasing in men and women worldwide.
  • Anal cancer is generally preceded by high-grade anal intraepithelial neoplasia (HGAIN), which is most prevalent in human immunodeficiency virus (HIV)-positive men who have sex with men.
  • Meta-analysis suggests that 80% of anal cancers could be avoided by vaccination against HPV 16/18.
  • Nearly half of all patients with anal cancer present with rectal bleeding.
  • According to the Surveillance Epidemiology and End Results (SEER) database, 50% of patients with anal cancer have disease localized to the anus, 29% have regional lymph node involvement or direct spread beyond the primary, and 12% have metastatic disease, while 9% have an unknown stage.
  • Clinical staging of anal carcinoma requires a digital rectal exam and a computed tomography scan of the chest, abdomen, and pelvis.
  • The 5-year relative survival rates are 80.1% for localized anal cancer, 60.7% for regional disease, and 29.4% for metastatic disease.
  • Part 2 of this two-part review will address the treatment of anal cancer, highlighting studies of chemoradiation.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / prevention & control. Mass Screening

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464850.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


Advertisement
4. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


5. Eng C, Pathak P: Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol; 2008 Dec;9(4-6):400-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options in metastatic squamous cell carcinoma of the anal canal.
  • Squamous cell carcinoma of the anal canal is a rare malignancy that is often cured with the combined modality therapy of chemoradiation.
  • Yet, a minority of patients will develop distant metastatic disease, an area of oncology in which a universally accepted approach has not been determined.
  • Consideration of platinum-based systemic chemotherapy is commonly provided for palliation with the optimal duration of therapy being largely unknown; the role of biologics and/or surgical resection of metastatic disease are anecdotal.
  • Here, we present a summary of the existing literature in the treatment of metastatic anal carcinoma in the hopes of providing insight and potential treatment alternatives for the practicing physician.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479383.001).
  • [ISSN] 1534-6277
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Meyer A, Bruns F, Richter K, Grünwald V, Karstens JH: Small cell cancer of the anal canal--case report of a rare tumor. Anticancer Res; 2007 Mar-Apr;27(2):1047-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the anal canal--case report of a rare tumor.
  • BACKGROUND: We report on a rare case of small cell cancer located at the anal canal.
  • CASE REPORT: A 41-year old woman presented with locally advanced small cell anal cancer and simultaneous hepatic and pulmonal deposits.
  • Due to metastatic disease, chemotherapy with etoposide and cisplatin was performed with mixed response after four cycles of chemotherapy.
  • CONCLUSION: In patients with metastatic small cell anal cancer chemotherapy remains the mainstay of therapy.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465242.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


7. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • Fourteen percent of T1 patients (3 out of 22), 42% of T2 patients (10 out of 24) and 40% of T3-4 patients (6 out of 15) assessed using CIm, had a change in their nodal or metastatic stage following FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


8. Yakovlev AE, Ellias Y: Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clin Med Res; 2008 Dec;6(3-4):103-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain.
  • Nearly 6,750,000 people suffer moderate to severe cancer-related pain each year.
  • Spinal cord stimulation (SCS) has been used with increased frequency for successful treatment of intractable cancer pain.
  • We present two cases of intractable, refractory-to-conventional treatment cancer pain that were successfully treated with SCS.
  • Case 1 reports a 51-year-old male with burning pain at the left groin site of inguinal metastases, post-surgical and intraoperative radiation therapy for treatment of squamous cell carcinoma of the anus.
  • Case 2 reports a 43-year-old woman with intractable, burning, throbbing, and shooting pain, post-debulking followed by radiation of a metastatic colon carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Electric Stimulation Therapy. Neuralgia / therapy. Spinal Cord. Spinal Cord Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hosp J. 1999;14(2):35-47 [10624231.001]
  • [Cites] J Pain Symptom Manage. 2004 Jan;27(1):72-8 [14711471.001]
  • [Cites] J Neurosurg. 2004 Mar;100(3 Suppl Spine):254-67 [15029914.001]
  • [Cites] Science. 1965 Nov 19;150(3699):971-9 [5320816.001]
  • [Cites] Surg Neurol. 1977 Apr;7(4):192 [300508.001]
  • [Cites] J Pain Symptom Manage. 1990 Feb;5(1):27-32 [2324558.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Jun 1;21(11):1344-50; discussion 1351 [8725927.001]
  • [Cites] Surg Neurol. 1996 Oct;46(4):363-9 [8876718.001]
  • [Cites] Lancet. 1996 Dec 21-28;348(9043):1698-701 [8973433.001]
  • [Cites] IEEE Trans Rehabil Eng. 1998 Sep;6(3):277-85 [9749905.001]
  • [Cites] Am Heart J. 1998 Dec;136(6):1114-20 [9842028.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):402-8 [10070441.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):138-45 [16643261.001]
  • [Cites] Pain Pract. 2007 Dec;7(4):345-7 [17986168.001]
  • (PMID = 19325172.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2670524
  •  go-up   go-down


9. Moreau MV, Tournier-Rangeard L, Kaminsky MC, Peiffert D: [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer]. Cancer Radiother; 2009 Jul;13(4):329-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative salvage treatment of mediastinal and pleuropulmonar metastatis from anal canal cancer].
  • [Transliterated title] Chimioradiothérapie de rattrapage pour métastases médiastinales et pleuropulmonaires d'un cancer du canal anal.
  • This case report presents a 57 years-old woman treated for a squamous cell carcinoma of the anal canal by radiochemotherapy and brachytherapy.
  • The particularity of this case lays on the fact that she presented a mediastinal and pleural metastatic evolution three years later, which was also treated by radiochemotherapy, leading to a complete remission of 50 months.
  • This observation is interesting for its curative treatment in metastatic cancer of the anal canal.
  • It also illustrates the radiosensibility of anal canal cancers, including metastatic situations, and raises the contribution of PET-scanner to evaluate the response to treatment and detect a recurrence.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell / secondary. Mediastinal Neoplasms / secondary. Pleural Neoplasms / secondary. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467897.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Compassionate Use Trials. Female. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


11. Kosugi C, Saito N, Murakami K, Ochiai A, Koda K, Ono M, Sugito M, Ito M, Oda K, Seike K, Miyazaki M: Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):398-402
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis.
  • BACKGROUND/AIMS: The impact of positron emission tomography was prospectively evaluated using 18 (F)-fluoro-deoxyglucose (FDG-PET) for the detection of lymph node (LN) metastasis in preoperative locally advanced colorectal adenocarcinoma, compared with computed tomography (CT) and pathologic findings.
  • METHODOLOGY: Fifty-three patients who were suspected of LN involvement by CT were staged preoperatively for LN metastasis using FDG-PET and CT.
  • Regional LNs were classified into 3 groups, N1, N2-3, and N4, according to the Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus (6th Edition).
  • The detection rate of the num ber of metastatic N1 LNs by CT was significantly higher than by FDG-PET, and not significantly in the N2-4 area.
  • CONCLUSIONS: While FDG-PET is markedly more sensitive than CT for detection of N4 LN involve. ment, the number of metastatic LNs is difficult to determine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613374.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


12. Starac D, Brestovac B, Sterrett GF, Smith DW, Frost FA: Can HPV DNA testing on FNA material determine anogenital origin in metastatic squamous cell carcinoma? Pathology; 2005 Jun;37(3):197-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can HPV DNA testing on FNA material determine anogenital origin in metastatic squamous cell carcinoma?
  • AIMS: Currently there are no diagnostic techniques that can precisely determine the primary site of a metastatic squamous cell carcinoma (SCC).
  • The aim of this study was to examine whether the finding of HR HPV DNA in a fine needle aspiration (FNA) of metastatic SCC could be used to determine a likely anogenital origin.
  • METHODS: Polymerase chain reaction (PCR) and viral sequencing were used to identify HR HPV DNA in cell block and needle rinse material derived from FNA samples in a series of metastatic SCC.
  • RESULTS: HPV DNA was detected in nine of 12 (75%) metastatic anogenital SCC, and type 16 was sequenced in seven.
  • HPV DNA was detected in only one of 18 (5.6%) metastatic SCC from other sites such as lung, oral cavity and skin.
  • HPV DNA detection was the major indicator to the primary site in one occult tumour and several where the previous diagnosis of anogenital cancer was not known at presentation.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Papillomaviridae / genetics. Tumor Virus Infections / diagnosis. Urogenital Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175891.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


13. Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, Haller D: Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282. Invest New Drugs; 2006 Sep;24(5):447-54
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: An eastern cooperative oncology group study E7282.
  • Metastatic anal cancer is a rare disease in the Western hemisphere and current treatment modalities are not effective.
  • In this study, patients with advanced epithelial cancer of the anal canal received MAP followed by Bleomycin and CCNU upon progression of disease.
  • The combination therapy of MAP followed by Bleomycin and CCNU for patients with advanced anal cancer, not amenable to radiotherapy or surgery, results in a moderate objective response but with moderate toxicities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763788.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 66636; United States / NCI NIH HHS / CA / CA13650; United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA25988
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 7BRF0Z81KG / Lomustine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, Martin RC, Scoggins CR, Tanabe KK, Michaelson JS, Kooby DA, Staley CA, Schulick RD, Vauthey JN, Abdalla EK, Curley SA, Choti MA, Elias D: Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol; 2007 Oct;14(10):2807-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis.
  • BACKGROUND: The role of hepatic resection for metastatic squamous cell carcinoma (SCC) remains unknown.
  • The current study evaluates the role of hepatic resection in patients with metastatic SCC to the liver.
  • METHODS: Between 1988 and 2006, 52 patients underwent hepatic resection of metastatic SCC at eight major cancer centers.
  • RESULTS: Primary SCC site was anal (n = 27), head/neck (n = 12), lung (n = 4), esophagus (n = 2), and other (n = 7).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / secondary. Electrocoagulation. Esophageal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Hepatectomy. Liver Neoplasms / secondary. Lung Neoplasms / surgery


15. Haberstich R, Tuech JJ, Wilt M, Rodier JF: Anal localization as first manifestation of metastatic ductal breast carcinoma. Tech Coloproctol; 2005 Dec;9(3):237-8
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal localization as first manifestation of metastatic ductal breast carcinoma.
  • The incidence of extrahepatic gastrointestinal metastases from breast cancer is reported in the literature only as necroscopy studies (6-18%); they usually originate from lobular or a mixed ductal-lobular subtype.
  • We report here a case of rectal metastasis from an invasive ductal carcinoma (IDC).
  • This is to our knowledge, the first recorded instance of an anal metastasis from IDC.
  • [MeSH-major] Anus Neoplasms / secondary. Anus Neoplasms / therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Nitriles / administration & dosage. Triazoles / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328121.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


16. Tomimaru Y, Ohue M, Noura S, Tanida T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1776-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer].
  • A 63-year-old man with a history of anal fistula was admitted to our hospital because the anal pain didn't disappear after the operation.
  • On digital examination, a hard mass measuring 3.0 cm in diameter was found at the anal canal.
  • Colonoscopy revealed another rectal cancer at 15 cm from anal verge.
  • Biopsy of the tumor also showed moderately differentiated adenocarcinoma, resembling the anal canal tumor.
  • Because the histological findings of both tumors were nearly identical, we considered that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal fistula.
  • The patient underwent anterior resection for the rectal cancer, and a local resection for the anal canal cancer.
  • We may suggest from these results that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / complications. Rectal Neoplasms / pathology


17. Fayaz S, Vasishta S, Motawy M: Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy. Gulf J Oncolog; 2007 Jul;(2):65-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report of long term survivor of metastatic cloacogenic carcinoma of the anal canal with chemotherapy.
  • A fifty-two years old Egyptian lady, case of cloacogenic carcinoma of anal canal with extensive liver metastasis showed complete remission with 5-Fluorouracil (5FU) and Cis-Dichlorodiammineplatinum(CDDP) chemotherapy only and remains disease free five & haf years after therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Liver Neoplasms / drug therapy. Survivors

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084726.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kuwait
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Sato H, Koh PK, Bartolo DC: Management of anal canal cancer. Dis Colon Rectum; 2005 Jun;48(6):1301-15
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal canal cancer.
  • PURPOSE: Chemoradiotherapy has replaced radical surgery as the initial treatment of choice for anal canal cancer.
  • The roles of these therapeutic modalities are discussed and recommendations on management of anal canal cancer are made based on currently available evidence.
  • METHODS: Literature on management of anal canal cancer from January 1970 to July 2003 obtained via MEDLINE was reviewed.
  • Reports on anal margin cancers were excluded.
  • RESULTS: Randomized, prospective, Phase 3 trials in Europe and the United States showed that chemoradiotherapy with 5-fluorouracil and mitomycin C was superior in local control, colostomy-free rate, progression-free survival, and cancer-specific survival compared with radiation alone.
  • Few studies addressed the treatment of metastatic disease, which remains a major cause of mortality.
  • [MeSH-major] Anus Neoplasms / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793642.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 116
  •  go-up   go-down


20. Crowley C, Winship AZ, Hawkins MA, Morris SL, Leslie MD: Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation? Clin Oncol (R Coll Radiol); 2009 Jun;21(5):376-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?
  • AIMS: Chemoradiation is the standard of care for the treatment of anal canal cancer, with surgery reserved for salvage.
  • MATERIALS AND METHODS: Between August 1998 and August 2004, 30 patients with biopsy-proven squamous cell anal canal cancer were treated with chemoradiation using one phase of treatment throughout.
  • Four patients relapsed and all were salvaged with surgery; two for local disease requiring abdominoperineal resection, one with an inguinal nodal relapse requiring inguinofemoral block dissection and one for metastatic disease to the liver who underwent liver resection.
  • CONCLUSIONS: This single-centre retrospective study supports the treatment for selected cases of anal canal cancer with smaller than standard radiation fields, avoiding prophylactic inguinal nodal irradiation.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Lymphatic Irradiation. Radiation Injuries / prevention & control
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Female. Humans. Inguinal Canal. Male. Middle Aged. Patient Compliance. Pelvis. Radiation Dosage. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282157.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Metastatic disease spread to lymph nodes, viscera and bone was recorded.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • The patient was administered chemotherapy with 5-fluorouracil and cisplatin (5-FU/CDDP) to the metastatic lymph node.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


24. Hirche C, Dresel S, Krempien R, Hünerbein M: Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience. Ann Surg Oncol; 2010 Sep;17(9):2357-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy by indocyanine green retention fluorescence detection for inguinal lymph node staging of anal cancer: preliminary experience.
  • BACKGROUND: There is some evidence that sentinel lymph node (SLN) biopsy guided by dye injection and/or radioisotopes can improve staging of inguinal lymph nodes (LNs) in anal cancer.
  • This study was performed to investigate the feasibility of fluorescence detection of SLN and lymphatic mapping in anal cancer.
  • METHODS: Twelve patients with anal cancer without evidence for inguinal LN involvement were included in the study.
  • Metastatic involvement of the SLN was found in 2 of 10 patients versus 2 of 9 patients.
  • Patients with metastatic involvement of the SLN received extended radiation field with inguinal boost.
  • CONCLUSIONS: ICG fluorescence imaging allows intraoperative lymphatic mapping and transcutaneous SLN detection for selective biopsy of inguinal SLN in anal cancer.
  • [MeSH-major] Anus Neoplasms / pathology. Indocyanine Green. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2011 Mar;18(3):901; author reply 902 [20717732.001]
  • (PMID = 20217256.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


25. Hida J, Okuno K, Yasutomi M, Yoshifuji T, Matsuzaki T, Uchida T, Ishimaru E, Tokoro T, Shiozaki H: Number versus distribution in classifying regional lymph node metastases from colon cancer. J Am Coll Surg; 2005 Aug;201(2):217-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number versus distribution in classifying regional lymph node metastases from colon cancer.
  • BACKGROUND: Metastasis to regional lymph nodes from colon cancer is an important prognostic factor.
  • In the TNM classification, node metastases are classified into three grades based on the number of metastatic nodes.
  • In the Japanese General Rules for Clinical and Pathologic Studies on Cancer of the Colon, Rectum, and Anus (JGR), node metastases are classified into four grades based on the distribution of metastatic nodes.
  • STUDY DESIGN: Based on the findings of node metastases in 164 patients with colon cancer obtained by the clearing method, node classifications by the JGR and TNM classifications were compared.
  • CONCLUSIONS: In the classification of regional node metastases from colon cancer, the JGR classification showed a wider range in distribution and 5-year survival rate compared with the TNM system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038819.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


26. Kocak Z, Saynak M, Oz-Puyan F, Cicin I, Cosar-Alas R, Caloglu M, Altiay G, Uzunoglu S: Inguinal lymph node as the only evidence of progressive lung cancer. Rev Port Pneumol; 2008 Sep-Oct;14(5):709-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal lymph node as the only evidence of progressive lung cancer.
  • Tumours that metastasise to groin nodes most frequently originate in genital and reproductive organs, skin, rectum or anus, or urinary bladder.
  • The primary tumours of these cases were malignant mesothelioma, salivary duct and breast carcinoma.
  • In this paper, we report a case of carcinoma of the lung metastatic to an inguinal lymph node as the only evidence of progressive lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Disease Progression. Humans. Inguinal Canal. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781272.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


27. Cummings BJ: Current management of anal canal cancer. Semin Oncol; 2005 Dec;32(6 Suppl 9):S123-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of anal canal cancer.
  • Combined-modality therapy consisting of radiation therapy and 5-fluorouracil plus mitomycin remains the standard treatment for localized anal canal cancer, permitting preservation of organ function and achieving high response and survival rates.
  • Metastatic disease is less responsive to chemoradiation treatment.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399449.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


28. Tougeron D, Tougeron-Brousseau B, Nasser Z, Benzerroug M, Lefebure B, Hamidou H, Michel P, Muraine M: Unusual iris metastasis from anal cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e1-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual iris metastasis from anal cancer: a case report.
  • We report a case of anal cancer with iris metastasis and summarize the iris metastasis literature.
  • A 69 years old woman with a history of anal cancer presented with a visual field loss.
  • Because of worse prognosis of metastatic cancer and any ocular complications, the patient was treated by radiotherapy which allowed a clinical improvement.
  • Anal carcinoma can metastasize to the iris.
  • [MeSH-major] Anus Neoplasms / pathology. Iris Neoplasms / secondary

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294934.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • By implication, these factors favour the centralization of treatment for this uncommon cancer to a multidisciplinary oncology team.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Itabashi M, Tada Y, Bamba Y, Takemoto K, Yoshimura Y, Kimura M, Hirosawa T, Ogawa S, Kameoka S: Case of peritoneal dissemination of colon cancer in which PET/CT was useful in determining the indicated surgical procedure. Int Surg; 2009 Jan-Feb;94(1):80-3
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of peritoneal dissemination of colon cancer in which PET/CT was useful in determining the indicated surgical procedure.
  • The right half of the colon was resected in a 70-year-old woman in August 2002 for ascending colon cancer.
  • Barium enema findings revealed an ileal constriction approximately 25 cm from the anastomosed site toward the anus.
  • Surgical findings revealed a roughly 2-cm peritoneal metastatic focus and ileal constriction.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099433.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


31. Rouzier R, Preti M, Sideri M, Paniel BJ, Jones RW: A suggested modification to FIGO stage III vulvar cancer. Gynecol Oncol; 2008 Jul;110(1):83-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A suggested modification to FIGO stage III vulvar cancer.
  • OBJECTIVE: FIGO Stage III vulvar cancer includes tumors that invade the lower urethra, vagina, or anus, and/or tumors that have metastasized to the inguino-femoral lymph nodes of one groin.
  • We hypothesized that locally advanced stage III vulvar cancer and regional metastatic stage III vulvar cancer (lymph node involvement) have different prognoses.
  • METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) registry public use data tapes, we identified patients diagnosed with vulvar carcinoma from 1988 through 2004.
  • The survival difference between stage III patients with locally advanced vulvar cancer and stage III patients with regional metastatic node(s) disease was highly significant (P<10(-10)).
  • The 5-year and 10-year OS of patients with locally advanced vulvar tumors without metastatic nodes were 62% and 47%, respectively.
  • The 5-year and 10-year OS of patients with regional metastatic node(s) disease were 39% and 27%, respectively.
  • Separating locally advanced stage III and regional metastatic stage III disease would improve discrimination (concordance index: 72% vs 69% with the actual staging system).
  • CONCLUSION: Involvement of the inguinal lymph nodes in FIGO (1988) stage III patients carries a significantly worse prognosis compared with invasion of the lower urethra, vagina or anus alone.

  • Genetic Alliance. consumer health - Vulvar cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18436291.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • We report a female patient with refractory anal cancer who achieved an excellent response to the combination of cetuximab and irinotecan after having failed single-agent irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


33. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


34. Vilbergsson E, Isaksson HJ, Möller PH: [Case report: facial skin metastasis from rectal adenocarcinoma]. Laeknabladid; 2010 Feb;96(2):109-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colonoscopy revealed a tumor located 10 to 15cm from the anus.
  • Biopsy showed metastatic signetring adenocarcinoma.
  • Colorectal metastatic lesions to the skin are rare findings, especially metastasis to the face.
  • Key words: Rectal cancer, metastases, skin.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Facial Neoplasms / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Biopsy. Colonoscopy. Humans. Male. Neoplasm Invasiveness. Peritoneal Neoplasms / secondary. Urinary Bladder Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20118505.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


35. Amano K, Ishibashi K, Nakada H, Okada N, Miyazaki T, Gonda T, Ishida H, Takahashi T: [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2025-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report].
  • We reported an elderly case of squamous cell carcinoma of the anal canal which showed complete response following radiotherapy alone.
  • An 86-year-old man complaining of anal bleeding and pain was admitted.
  • Biopsy revealed squamous cell carcinoma.
  • Magnetic resonance imaging did not show any metastatic lesions.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


36. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR: L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer; 2007 Jul 15;121(2):257-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
  • More recently, activating KIT mutations have been described in rare cases of metastatic melanoma, without further reference to their clinical phenotypes.
  • In this study, we investigated a group of anal melanomas for the presence of BRAF, NRAS, KIT and PDGFRA mutations.
  • No BRAF or PDGFRA mutations were identified in either KIT positive or negative anal melanomas.
  • These results suggest that a subset of anal melanomas show activating KIT mutations, which are susceptible for therapy with specific kinase inhibitors.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17372901.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / P01 CA064593; United States / NCI NIH HHS / CA / P30 CA008748; United States / NIDDK NIH HHS / DK / HL/DK55748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; RBZ1571X5H / Dasatinib
  •  go-up   go-down


37. Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, Fox T, Esteves F, Landry J, Godette K: PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys; 2007 Sep 1;69(1):155-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: From March to November 2003, 20 patients with rectal cancer and 3 patients with anal cancer were treated with preoperative or definitive chemoradiation, respectively.
  • For 25% of patients with rectal cancer, PET detected distant metastases and changed overall management.
  • Ten rectal cancer patients underwent surgery.
  • Positron emission tomography can change the management for anorectal tumors by early detection of metastatic disease or disease outside standard radiation fields.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Rectal Neoplasms / radiography. Rectal Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707268.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


38. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • The patient is now given 5-fluorouracil/cisplatin in addition to external radiotherapy (57.5 Gy) to the metastatic lymph node.
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Pocard M, Sabourin JC: [Sentinel lymph node biopsy in gastro-intestinal surgery: facts and future implications]. J Chir (Paris); 2008 Dec;145 Spec no. 4:12S17-12S20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.
  • [MeSH-minor] Anus Neoplasms / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures. Humans. Neoplasm Staging. Prognosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19194353.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 99
  •  go-up   go-down


40. Iagaru A, Kundu R, Jadvar H, Nagle D: Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med; 2009 Jan-Apr;12(1):26-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
  • Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies.
  • Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients.
  • Metastatic nodal involvement was confirmed by pathology in 2 patients; in the other 2 patients pathology showed reactive follicular hyperplasia.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330178.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Khaled A, Hammami H, Fazaa B, Kourda N, Kamoun MR, Ben Jilany S, Zoghlami A: Primary amelanotic anorectal melanoma: an uncommon neoplasia with poor prognosis. Pathologica; 2009 Jun;101(3):126-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Anorectal melanoma is a rare and aggressive mucosal cancer.
  • Herein, we report a case of amelanotic anorectal malignant melanoma with an unusual metastatic deposit in the vulva and also review the literature.
  • CASE REPORT: A 67-year-old woman presented with a history of prolapse of an anal tumour.
  • Anorectal melanoma is most common in the rectum, followed by the anal canal.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma, Amelanotic / secondary. Rectal Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Vulvar Neoplasms / metabolism. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886548.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


42. Bliznashki I, Minev M, Mikhova A, Velev M: [A rare case of Gardner's syndrome complicated with rectal carcinoma]. Khirurgiia (Sofiia); 2007;(3):60-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare case of Gardner's syndrome complicated with rectal carcinoma].
  • Eight of them have died by colorectal carcinoma.
  • If undetected or untreated virtually all patients develop colonic carcinoma at a young age.
  • He had multiple adenomatous polyposis of colon, rectal cancer, osteomas of skull bones, subcutaneous fibromas and lipomas.
  • His father has had also multiple polyposis with malignancy and metastatic lesions and he has died at age of 49 years.
  • We performed total proctocolectomy with definitive iliac anus and cholecystectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437113.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


43. Sahai A, Kodner IJ: Premalignant neoplasms and squamous cell carcinoma of the anal margin. Clin Colon Rectal Surg; 2006 May;19(2):88-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Premalignant neoplasms and squamous cell carcinoma of the anal margin.
  • Premalignant and malignant lesions of the anal margin are rare.
  • Understanding anal anatomy and performing a biopsy of any suspicious lesions are essential in avoiding a delay in diagnosis and appropriately treating these tumors.
  • Combined multimodality treatment has come to play an important role in managing patient with more advanced or metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):444-50 [15747068.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Arch Dermatol. 1999 Jul;135(7):790-3 [10411153.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):945-51 [10411443.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Surg Oncol. 1996 Feb;5(1):29-35 [8837302.001]
  • [Cites] J Am Acad Dermatol. 1992 Dec;27(6 Pt 1):979-82 [1479105.001]
  • [Cites] Dis Colon Rectum. 1992 May;35(5):422-9 [1568392.001]
  • [Cites] Lasers Surg Med. 1991;11(4):385-7 [1895869.001]
  • [Cites] JAMA. 1991 Aug 14;266(6):816-9 [1865520.001]
  • [Cites] Br J Dermatol. 1988 Aug;119(2):231-40 [3166941.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):321-38 [15137960.001]
  • [Cites] J Surg Oncol. 2004 May 1;86(2):55-62; discussion 63 [15112245.001]
  • [Cites] Cancer Invest. 2003 Jun;21(3):452-64 [12901291.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Apr;15(2):321-44, vi [11370496.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Br J Surg. 1988 Nov;75(11):1089-92 [2850073.001]
  • [Cites] Dis Colon Rectum. 1987 Apr;30(4):263-6 [3030676.001]
  • [Cites] Dis Colon Rectum. 1988 Jun;31(6):419-22 [3288448.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):273-8 [3359896.001]
  • [Cites] JAMA. 1987 Jan 23-30;257(4):516-8 [3795434.001]
  • [Cites] Dis Colon Rectum. 1983 Nov;26(11):712-5 [6628143.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):375-88 [15137963.001]
  • (PMID = 20011315.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780101
  • [Keywords] NOTNLM ; Anus neoplasms / Bowen's disease / Paget's disease / squamous cell cancer
  •  go-up   go-down


44. Barriger RB, Calley C, Cárdenes HR: Treatment of anal carcinoma in immune-compromised patients. Clin Transl Oncol; 2009 Sep;11(9):609-14
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of anal carcinoma in immune-compromised patients.
  • This study was undertaken to evaluate local control (LC), overall survival (OS) and toxicity in immune-compromised patients with anal carcinoma treated with radiotherapy with or without chemotherapy.
  • METHODS: We identified 25 patients with anal carcinoma and human immunodeficiency virus (HIV) infection or history of solid-organ transplant on chronic medical immune-suppression.
  • One patient had metastatic disease at diagnosis.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Immunocompromised Host

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19776001.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


45. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Zurada JM, Ward KM, Grossman ME: Henoch-Schönlein purpura associated with malignancy in adults. J Am Acad Dermatol; 2006 Nov;55(5 Suppl):S65-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of patients (55%) developed HSP within 1 month of cancer diagnosis or detection of metastases.
  • We also advise that patients with a known history of malignancy who present with HSP be evaluated for metastatic disease.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Prostatic Neoplasms / complications. Purpura, Schoenlein-Henoch / etiology
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carcinoma, Renal Cell / complications. Female. Humans. Kidney Neoplasms / complications. Male. Middle Aged

  • Genetic Alliance. consumer health - Henoch-Schonlein purpura.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052537.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, Glynne-Jones R: Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? Int J Radiat Oncol Biol Phys; 2010 Nov 1;78(3):715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome?
  • PURPOSE: To describe the MRI appearances of squamous cell carcinoma of the anal canal before and after chemoradiation and to assess whether MRI features predict for clinical outcome.
  • METHODS AND MATERIALS: Thirty-five patients (15 male, 20 female; mean age 60.8 years) with histologically proven squamous cell cancer of the anal canal underwent MRI before and 6-8 weeks after definitive chemoradiation.
  • At a median follow-up of 33.5 months, 25 patients (71.4%) remained disease-free; 10 patients (28.6%) had locoregional or metastatic disease.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Anal Canal / pathology. Analysis of Variance. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171812.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Methy N, Bedenne L, Bonnetain F: Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists. BMC Cancer; 2010;10:277
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials.
  • The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists.
  • Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL).
  • METHODS: In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of cancer clinical trials.
  • Then they had to suggest potential surrogate endpoints for OS in each of the following tumour sites: oesophagus, stomach, liver, pancreas, biliary tract, lymphoma, colon, rectum, and anus.
  • Half of them thought it was not relevant to study QoL as surrogate for OS.DFS, in the neoadjuvant settings or early stages, and PFS, in the non operable or metastatic settings, were ranked first, with a frequency of more than 69% in 20 out of 22 settings.
  • PFS was proposed in association with QoL in metastatic primary liver and stomach cancers (both 81%).
  • This composite endpoint was ranked second in metastatic oesophageal (69%), colorectal (56%) and anal (56%) cancers, whereas QoL alone was also suggested in most metastatic situations.Other endpoints frequently suggested were R0 resection in the neoadjuvant settings (oesophagus (69%), stomach (56%), pancreas (75%) and biliary tract (63%)) and response.
  • An unexpected endpoint was metastatic PFS in non operable oesophageal (31%) and pancreatic (44%) cancers.
  • Quality and results of surgical procedures like sphincter preservation were also cited as eligible surrogate endpoints in rectal (19%) and anal (50% in case of localized disease) cancers.
  • Except for alpha-FP kinetic in hepatocellular carcinoma (13%) and CA19-9 decline (6%) in pancreas, few endpoints based on biological or tumour markers were proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2008 Jan;53(1):6-9 [17764823.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5218-24 [18024867.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3721-6 [18669458.001]
  • [Cites] Stat Methods Med Res. 2008 Oct;17(5):529-35 [18285442.001]
  • [Cites] Pharm Stat. 2008 Oct-Dec;7(4):263-9; discussion 270-1 [17847030.001]
  • [Cites] Int J Clin Oncol. 2009 Apr;14(2):102-11 [19390940.001]
  • [Cites] Bull Cancer. 2009 May;96(5):591-5 [19423485.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2874-80 [19414672.001]
  • [Cites] Ann Oncol. 2010 Jan;21(1):7-12 [19901012.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):518-24 [19759186.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8564-5 [16260691.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] J Adv Nurs. 2000 Oct;32(4):1008-15 [11095242.001]
  • [Cites] Clin Pharmacol Ther. 2001 Mar;69(3):89-95 [11240971.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1404-11 [12663734.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):545-9 [15033657.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(20):7-9 [8750460.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):605-13 [8815760.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3662-73 [9817289.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 [15647217.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):504-9 [16136026.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] Stat Med. 2006 Jan 30;25(2):183-203 [16252272.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1344-50 [16730974.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):703-4 [16945763.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):741-6 [16945769.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003 [17596575.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3572-5 [17704403.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4569-74 [17876008.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4562-8 [17876010.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:19-21 [18434634.001]
  • (PMID = 20537166.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904280
  •  go-up   go-down


49. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol; 2008 Dec;5(12):737-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
  • DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936790.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


50. Fogliata A, Nicolini G, Alber M, Asell M, Clivio A, Dobler B, Larsson M, Lohr F, Lorenz F, Muzik J, Polednik M, Vanetti E, Wolff D, Wyttenbach R, Cozzi L: On the performances of different IMRT Treatment Planning Systems for selected paediatric cases. Radiat Oncol; 2007;2:7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumour types were: one extraosseous, intrathoracic Ewing Sarcoma; one mediastinal Rhabdomyosarcoma; one metastatic Rhabdomyosarcoma of the anus; one Wilm's tumour of the left kidney with multiple liver metastases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 2000 May 30;52(3):261-8 [10841956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):497-504 [17084557.001]
  • [Cites] Med Dosim. 2001 Spring;26(1):65-9 [11417509.001]
  • [Cites] Phys Med Biol. 2001 Jul;46(7):1997-2007 [11474940.001]
  • [Cites] Phys Med Biol. 2001 Dec;46(12):3229-39 [11768502.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):224-35 [11777642.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):599-605 [11849779.001]
  • [Cites] Med Dosim. 2002 Summer;27(2):115-20 [12074462.001]
  • [Cites] Cancer Invest. 2002;20(4):437-51 [12094538.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1111-6 [12128109.001]
  • [Cites] Oral Oncol. 2002 Sep;38(6):597-604 [12167438.001]
  • [Cites] Pediatr Clin North Am. 2002 Oct;49(5):1107-29 [12430628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 [12694826.001]
  • [Cites] Phys Med Biol. 2003 Mar 21;48(6):707-27 [12699190.001]
  • [Cites] Med Phys. 2003 Sep;30(9):2332-9 [14528955.001]
  • [Cites] Radiother Oncol. 2003 Dec;69(3):251-8 [14644484.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):663-73 [14967418.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):215-22 [15191011.001]
  • [Cites] Med Phys. 1993 Mar-Apr;20(2 Pt 1):311-8 [8497215.001]
  • [Cites] Med Phys. 1994 Mar;21(3):343-56 [8208209.001]
  • [Cites] Med Phys. 1994 Jul;21(7):1031-41 [7968833.001]
  • [Cites] Med Phys. 1994 Aug;21(8):1237-44 [7799865.001]
  • [Cites] Med Phys. 1995 Jul;22(7):1141-56 [7565389.001]
  • [Cites] Br Med Bull. 1996 Oct;52(4):873-86 [9039737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):667-72 [9231693.001]
  • [Cites] Med Phys. 1998 Mar;25(3):321-33 [9547499.001]
  • [Cites] Phys Med Biol. 1999 Feb;44(2):479-93 [10070796.001]
  • [Cites] Med Dosim. 2004 Winter;29(4):247-53 [15528065.001]
  • [Cites] Acta Oncol. 2005;44(5):467-74 [16118080.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):300-10 [16153730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Apr;2(4):211-7 [16264936.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):66-70 [16462506.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7 [16618572.001]
  • [Cites] Radiat Oncol. 2006;1:7 [16722599.001]
  • [Cites] Phys Med Biol. 2006 Nov 21;51(22):5785-807 [17068365.001]
  • [Cites] Med Phys. 2000 Sep;27(9):2093-9 [11011738.001]
  • (PMID = 17302972.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1803794
  • [General-notes] NLM/ Original DateCompleted: 20070809
  •  go-up   go-down


51. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


52. Kuga Y, Tanaka T, Arita M, Usui Y, Okanobu H, Numata Y, Miwata T, Yoshimi S, Murakami E, Moriya T, Ohya T, Nishida T: [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1923-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiotherapy using S-1 and CDDP for left inguinal lymph node metastasis of anal canal carcinoma].
  • We report a case of left inguinal lymph node metastasis of anal canal carcinoma, treated effectively with chemotherapy consisting of S-1 and CDDP combined with radiotherapy.
  • In February 2006, a 76-year-old woman underwent resection of a tumor diagnosed as squamous cell carcinoma of the anal canal.
  • Biopsy was performed, and specimens were shown to include squamous cell carcinoma cells.
  • The metastatic tumor in the lymph node responded well to the treatment and decreased remarkably in size by December 2007.
  • Chemotherapy consisting of S-1 and CDDP concurrent with radiotherapy maybe effective for treating metastatic lymph node metastasis of anal canal carcinoma.
  • [MeSH-major] Anal Canal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis
  • [MeSH-minor] Administration, Oral. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Humans. Inguinal Canal. Injections, Intravenous. Oxonic Acid / administration & dosage. Radiotherapy Dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • Four patients died with metastatic disease, 1 is alive with pelvic recurrence at 55 months, and 1 is alive without evidence of disease at 19 months follow-up.
  • Mean delay of cancer diagnosis was 11 months.
  • Periodical cancer surveillance should be performed in all patients with long-standing perianal CD fistulae.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology


54. Fogliata A, Yartsev S, Nicolini G, Clivio A, Vanetti E, Wyttenbach R, Bauman G, Cozzi L: On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases. Radiat Oncol; 2009;4:2
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To evaluate the performance of three different advanced treatment techniques on a group of complex paediatric cancer cases.
  • The tumour types were: extraosseous, intrathoracic Ewing Sarcoma; mediastinal Rhabdomyosarcoma; metastasis of base of skull with bone, para-nasal and left eye infiltration from Nephroblastoma of right kidney; metastatic Rhabdomyosarcoma of the anus; Wilm's tumour of the left kidney with multiple liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 2000 May 30;52(3):261-8 [10841956.001]
  • [Cites] Med Dosim. 2002 Summer;27(2):115-20 [12074462.001]
  • [Cites] Acta Oncol. 2009;48(2):245-50 [18720056.001]
  • [Cites] Radiother Oncol. 2008 Dec;89(3):254-62 [18760851.001]
  • [Cites] Radiother Oncol. 2008 Nov;89(2):135-40 [18707783.001]
  • [Cites] Radiother Oncol. 2008 Nov;89(2):180-91 [18692929.001]
  • [Cites] Br J Radiol. 2008 Nov;81(971):872-80 [18941047.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):979-86 [18325681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):220-5 [18068310.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):685-8 [18040613.001]
  • [Cites] Technol Cancer Res Treat. 2007 Aug;6(4):355-60 [17668944.001]
  • [Cites] J Appl Clin Med Phys. 2006 Summer;7(3):1-11 [17533339.001]
  • [Cites] Radiat Oncol. 2007;2:7 [17302972.001]
  • [Cites] Phys Med Biol. 2007 Mar 7;52(5):1363-85 [17301460.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):497-504 [17084557.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):653-9 [17072523.001]
  • [Cites] Semin Radiat Oncol. 2006 Oct;16(4):199-208 [17010902.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1375-80 [16750314.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):313-21 [16490269.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7 [16618572.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Apr;2(4):211-7 [16264936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Br J Radiol. 2005 Jun;78(930):548-52 [15900062.001]
  • [Cites] Phys Med Biol. 2005 Apr 21;50(8):1767-90 [15815095.001]
  • [Cites] Med Dosim. 2004 Winter;29(4):247-53 [15528065.001]
  • [Cites] Br Med Bull. 1996 Oct;52(4):873-86 [9039737.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 May;16(3):215-22 [15191011.001]
  • [Cites] Phys Med Biol. 2003 Jul 7;48(13):1933-43 [12884926.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8 [12694826.001]
  • [Cites] Pediatr Clin North Am. 2002 Oct;49(5):1107-29 [12430628.001]
  • (PMID = 19144155.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protons
  • [Other-IDs] NLM/ PMC2672932
  •  go-up   go-down


55. Cummings BJ: Metastatic anal cancer: the search for cure. Onkologie; 2006 Feb;29(1-2):5-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic anal cancer: the search for cure.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Onkologie. 2006 Feb;29(1-2):30-2 [16514253.001]
  • (PMID = 16514247.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement